Two experiments were conducted to determine whether dosage of estradiol valerate (EV) or day of estrous cycle when treatment was administered affected response to Syncro-Mate-B (SMB). Suckled beef cows received a 6-mg Norgestomet (NOR) ear implant (in situ 9 d) and a 3-mg NOR i.m. injection. In Exp. 1, 74 cows received NOR treatments concurrently with either 5 or 6 mg of EV administered i.m. on either d 1, 3, or 5 of an estrous cycle (estrus = d 1). In Exp. 2, 169 cows received NOR treatments concurrently with either 5, 7, or 9 mg of EV administered i.m. on either d 3 or 9 of an estrous cycle. In Exp. 1, 67, 50 and 92%, respectively, of cows receiving 5 mg of EV on d 1, 3, or 5 had functional corpora lutea (CL) at implant removal, whereas 42, 75, and 77%, respectively, of cows receiving 6 mg of EV had functional CL at implant removal (dosage P greater than .10; day P less than .05). Synchronized estrous responses were 50, 33, and 23%, respectively, when cows received 5 mg of EV on d 1, 3, or 5, and 67, 33, and 38%, respectively, when cows received 6 mg of EV (dosage P greater than .10; day P less than .05). First-service pregnancy rate was decreased (P less than .05) in cows treated on d 5 (33%) compared with cows treated on d 1 (63%), but dosage of EV had no effect on pregnancy rate.(ABSTRACT TRUNCATED AT 250 WORDS)
From 1981 through 1986, BW, hip height, and scrotal circumference (SC) measurements were obtained on 329 bulls at the start of a 140-d gain test (SOT) and every 28 d to the end of test (EOT). Age, overall ADG, weight per day of age, ADG by period, and SC growth (cm/d) were calculated. Data were analyzed in two data sets because age of dam (AOD) and birth weights were unavailable between 1981 and 1983. Correlations of SC to other traits measured and probabilities for bulls attaining 30 or 32 cm SC by 365 d of age were calculated. Two adjusted 365-d SC (365-d SC) were calculated for each individual from regression analysis and from the following formula: 365-d SC = [(SCEOT-SCSOT)/140 d] x [365-ageSOT] + SCSOT. Except for ADG in Data Set 2, breed group differences (P less than .05) were observed for correlations of SC to all growth traits, age, and AOD. To attain 30 cm SC by 365 d of age with nearly 100% probability, Angus, Simmental and Zebu-derived bulls needed a 23-cm SCSOT, whereas continental (other than Simmental) and Polled Hereford bulls required a 26-cm SCSOT. Overall, 365-d SC means calculated by regression analysis or formula method did not differ (P greater than .10) for either data set.
Ruminant placentae produce at least two distinct subclasses of the growth hormone/prolactin gene family, the placental lactogens and prolactin-related proteins. Placental lactogens have been purified from cattle, goat and sheep placentae, and the amino acid sequences of bovine and ovine placental lactogen are known. Bovine and ovine placental lactogens are structurally more similar to prolactin than they are to growth hormone. In addition, six unique mRNAs have been described in cattle that encode prolactin-related proteins that are structurally distinct from ruminant placental lactogens. All characterized ruminant placental lactogens and prolactin-related proteins are products of chorionic binucleate cells, but specific biological functions of these placental hormones have not been elucidated. Ovine placental lactogen may modify maternal and fetal intermediary metabolism to provide energy substrates to the fetus. Bovine placental lactogen has been implicated as a luteotropic agent, and is also capable of stimulating mammogenesis and lactogenesis. No ruminant placental lactogen receptor has been structurally characterized, although they are presumed to be similar to either the growth hormone or prolactin receptor. Available technologies will allow many of the questions regarding the regulation, mechanism of action and function of these placental hormones to be addressed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.